{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T15:31:04Z","timestamp":1787153464845,"version":"build-2736575974"},"reference-count":100,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Endocrinology & Metabolism"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.beem.2025.102066","type":"journal-article","created":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T08:08:57Z","timestamp":1762416537000},"page":"102066","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Hyponatraemia and cancer"],"prefix":"10.1016","volume":"40","author":[{"given":"Laura","family":"Naldi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedetta","family":"Fibbi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giada","family":"Marroncini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dario","family":"Norello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Peri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"21","key":"10.1016\/j.beem.2025.102066_bib1","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1056\/NEJM200005253422107","article-title":"Hyponatremia","volume":"342","author":"Adrogu\u00e9","year":"2000","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.beem.2025.102066_bib2","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1007\/s11255-014-0839-2","article-title":"Hyponatremia: pathophysiology, classification, manifestations and management","volume":"46","author":"Rondon-Berrios","year":"2014","journal-title":"Int Urol Nephrol"},{"issue":"2","key":"10.1016\/j.beem.2025.102066_bib3","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.beem.2016.02.009","article-title":"The syndrome of inappropriate antidiuresis (SIAD)","volume":"30","author":"Cuesta","year":"2016","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.beem.2025.102066_bib4","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1053\/j.ajkd.2011.08.029","article-title":"Hyponatremia in hospitalized cancer patients and its impact on clinical outcomes","volume":"59","author":"Doshi","year":"2012","journal-title":"Am J Kidney Dis J Natl Kidney Found"},{"key":"10.1016\/j.beem.2025.102066_bib5","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.critrevonc.2016.03.010","article-title":"Hyponatremia in cancer patients: Time for a new approach","volume":"102","author":"Berardi","year":"2016","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.beem.2025.102066_bib6","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1186\/s12885-016-2610-9","article-title":"The occurrence of hyponatremia and its importance as a prognostic factor in a cross-section of cancer patients","volume":"16","author":"Castillo","year":"2016","journal-title":"BMC Cancer"},{"key":"10.1016\/j.beem.2025.102066_bib7","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1159\/000493245","article-title":"Hyponatremia in oncology patients","volume":"52","author":"Groh\u00e9","year":"2019","journal-title":"Front Horm Res"},{"issue":"3","key":"10.1016\/j.beem.2025.102066_bib8","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.mehy.2012.05.023","article-title":"Proposing the use of hyponatremia as a marker to help identify high risk individuals for lung cancer","volume":"79","author":"Kasi","year":"2012","journal-title":"Med Hypotheses"},{"issue":"3","key":"10.1016\/j.beem.2025.102066_bib9","first-page":"192","article-title":"A prospective study on hyponatraemia in medical cancer patients: epidemiology, aetiology and differential diagnosis","volume":"8","author":"Berghmans","year":"2000","journal-title":"Support Care Cancer J Multinatl Assoc Support Care Cancer"},{"issue":"20","key":"10.1016\/j.beem.2025.102066_bib10","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.1056\/NEJMcp066837","article-title":"Clinical practice. The syndrome of inappropriate antidiuresis","volume":"356","author":"Ellison","year":"2007","journal-title":"N Engl J Med"},{"issue":"10 1","key":"10.1016\/j.beem.2025.102066_bib11","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.amjmed.2013.07.006","article-title":"Diagnosis, evaluation, and treatment of hyponatremia: expert panel recommendations","volume":"126","author":"Verbalis","year":"2013","journal-title":"Am J Med"},{"issue":"1","key":"10.1016\/j.beem.2025.102066_bib12","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1053\/j.ajkd.2008.03.004","article-title":"A review of drug-induced hyponatremia","volume":"52","author":"Liamis","year":"2008","journal-title":"Am J Kidney Dis J Natl Kidney Found"},{"issue":"12","key":"10.1016\/j.beem.2025.102066_bib13","first-page":"1341","article-title":"Diagnosis and management of hyponatremia in cancer patients","volume":"15","author":"Raftopoulos","year":"2007","journal-title":"Support Care Cancer J Multinatl Assoc Support Care Cancer"},{"issue":"8","key":"10.1016\/j.beem.2025.102066_bib14","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1007\/s40618-025-02587-4","article-title":"Treatment with antidepressant drugs and hyponatremia: a network meta-analysis","volume":"48","author":"Norello","year":"2025","journal-title":"J Endocrinol Invest"},{"issue":"5","key":"10.1016\/j.beem.2025.102066_bib15","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0152079","article-title":"Risk of hyponatraemia in cancer patients treated with targeted therapies: a systematic review and meta-analysis of clinical trials","volume":"11","author":"Berardi","year":"2016","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.beem.2025.102066_bib16","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1007\/s10157-025-02635-6","article-title":"Water and electrolyte abnormalities in novel pharmacological agents for kidney disease and cancer","volume":"29","author":"Terashita","year":"2025","journal-title":"Clin Exp Nephrol"},{"key":"10.1016\/j.beem.2025.102066_bib17","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/1478-7547-4-10","article-title":"Cost of illness of hyponatremia in the United States","volume":"4","author":"Boscoe","year":"2006","journal-title":"Cost Eff Resour Alloc"},{"issue":"3","key":"10.1016\/j.beem.2025.102066_bib18","first-page":"621","article-title":"Hyponatraemia is a predictor of clinical outcome for malignant pleural mesothelioma","volume":"23","author":"Berardi","year":"2015","journal-title":"Support Care Cancer J Multinatl Assoc Support Care Cancer"},{"issue":"12","key":"10.1016\/j.beem.2025.102066_bib19","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0080451","article-title":"Moderate hyponatremia is associated with increased risk of mortality: evidence from a meta-analysis","volume":"8","author":"Corona","year":"2013","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.beem.2025.102066_bib20","doi-asserted-by":"crossref","first-page":"631","DOI":"10.6004\/jnccn.2006.0052","article-title":"Paraneoplastic syndromes associated with small cell lung cancer","volume":"4","author":"Gandhi","year":"2006","journal-title":"J Natl Compr Canc Netw"},{"issue":"4","key":"10.1016\/j.beem.2025.102066_bib21","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1038\/bjc.1990.133","article-title":"An overview of prognostic factors in small cell lung cancer. A report from the subcommittee for the management of lung cancer of the United Kingdom Coordinating Committee on Cancer Research","volume":"61","author":"Rawson","year":"1990","journal-title":"Br J Cancer"},{"issue":"5","key":"10.1016\/j.beem.2025.102066_bib22","first-page":"409","article-title":"Prognostic impact of hyponatraemia in patients with colorectal cancer","volume":"17","author":"Choi","year":"2015","journal-title":"Color Dis J Assoc Coloproctol Gt Br Irel"},{"issue":"4","key":"10.1016\/j.beem.2025.102066_bib23","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1038\/bjc.1993.425","article-title":"Combination chemotherapy for intermediate and high grade non-Hodgkin\u2019s lymphoma","volume":"68","author":"Dhaliwal","year":"1993","journal-title":"Br J Cancer"},{"issue":"3","key":"10.1016\/j.beem.2025.102066_bib24","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1002\/hep.22418","article-title":"Hyponatremia in cirrhosis: pathogenesis, clinical significance, and management","volume":"48","author":"Gin\u00e8s","year":"2008","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.beem.2025.102066_bib25","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1001\/archsurg.2008.522","article-title":"Indication of the extent of hepatectomy for hepatocellular carcinoma on cirrhosis by a simple algorithm based on preoperative variables","volume":"144","author":"Cescon","year":"2009","journal-title":"Arch Surg"},{"issue":"6","key":"10.1016\/j.beem.2025.102066_bib26","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1158\/1078-0432.CCR-07-1721","article-title":"Prognostic factors in renal cell carcinoma: association of preoperative sodium concentration with survival","volume":"14","author":"Vasudev","year":"2008","journal-title":"Clin Cancer Res J Am Assoc Cancer Res"},{"issue":"4","key":"10.1016\/j.beem.2025.102066_bib27","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.eururo.2013.10.013","article-title":"The impact of low serum sodium on treatment outcome of targeted therapy in metastatic renal cell carcinoma: results from the International Metastatic Renal Cell Cancer Database Consortium","volume":"65","author":"Schutz","year":"2014","journal-title":"Eur Urol"},{"issue":"2","key":"10.1016\/j.beem.2025.102066_bib28","first-page":"224","article-title":"Hyponatraemia in cancer: association with type of cancer and mortality","volume":"24","author":"Abu Zeinah","year":"2015","journal-title":"Eur. J. Cancer Care"},{"key":"10.1016\/j.beem.2025.102066_bib29","doi-asserted-by":"crossref","DOI":"10.1177\/1179554920936605","article-title":"The role of hyponatraemia before surgery in patients with radical resected pancreatic cancer","volume":"14","author":"Berardi","year":"2020","journal-title":"Clin Med Insights Oncol"},{"issue":"1","key":"10.1016\/j.beem.2025.102066_bib30","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s40487-020-00112-6","article-title":"Hyponatremia is a predictor of clinical outcome for resected biliary tract cancers: a retrospective single-center study","volume":"8","author":"Berardi","year":"2020","journal-title":"Oncol Ther"},{"issue":"4","key":"10.1016\/j.beem.2025.102066_bib31","doi-asserted-by":"crossref","DOI":"10.3390\/jcm9041218","article-title":"Validation of hyponatremia as a prognostic predictor in multiregional upper tract urothelial carcinoma","volume":"9","author":"Yeh","year":"2020","journal-title":"J Clin Med"},{"issue":"4","key":"10.1016\/j.beem.2025.102066_bib32","doi-asserted-by":"crossref","first-page":"836","DOI":"10.7150\/jca.28118","article-title":"Prognostic value of preoperative hyponatremia in patients with epithelial ovarian cancer","volume":"10","author":"Guo","year":"2019","journal-title":"J Cancer"},{"issue":"8","key":"10.1016\/j.beem.2025.102066_bib33","first-page":"4189","article-title":"Prognostic factors in small cell lung cancer: multivariate model based on 778 patients treated with chemotherapy with or without irradiation","volume":"46","author":"Osterlind","year":"1986","journal-title":"Cancer Res"},{"issue":"9","key":"10.1016\/j.beem.2025.102066_bib34","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/j.amjmed.2009.01.027","article-title":"Mortality after hospitalization with mild, moderate, and severe hyponatremia","volume":"122","author":"Waikar","year":"2009","journal-title":"Am J Med"},{"issue":"5","key":"10.1016\/j.beem.2025.102066_bib35","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.4103\/0973-1482.187296","article-title":"Prognostic significance of pretreatment sodium levels in patients of nonsmall cell lung cancer treated with pemetrexed-platinum doublet chemotherapy","volume":"14","author":"Doshi","year":"2018","journal-title":"J Cancer Res Ther"},{"issue":"12","key":"10.1016\/j.beem.2025.102066_bib36","first-page":"1050","article-title":"Impact of hyponatremia on survival of patients with metastatic renal cell carcinoma treated with molecular targeted therapy","volume":"19","author":"Kawashima","year":"2012","journal-title":"Int J Urol J Jpn Urol Assoc"},{"issue":"11","key":"10.1016\/j.beem.2025.102066_bib37","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1080\/0284186X.2018.1477256","article-title":"Hyponatremia associates with poor outcome in metastatic renal cell carcinoma patients treated with everolimus: prognostic impact","volume":"57","author":"Penttil\u00e4","year":"2018","journal-title":"Acta Oncol"},{"issue":"1","key":"10.1016\/j.beem.2025.102066_bib38","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1530\/EJE-22-0023","article-title":"Prognostic value of dysnatremia for survival in neuroendocrine neoplasm patients","volume":"187","author":"Refardt","year":"2022","journal-title":"Eur J Endocrinol"},{"issue":"5","key":"10.1016\/j.beem.2025.102066_bib39","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1007\/s10620-020-06380-6","article-title":"Lower serum sodium levels are associated with the therapeutic effect of sorafenib on hepatocellular carcinoma","volume":"66","author":"Kegasawa","year":"2021","journal-title":"Dig Dis Sci"},{"issue":"12","key":"10.1016\/j.beem.2025.102066_bib40","first-page":"7461","article-title":"Predictive and prognostic significance of sodium levels in patients with NSCLC treated by erlotinib","volume":"34","author":"Svaton","year":"2014","journal-title":"Anticancer Res"},{"issue":"1","key":"10.1016\/j.beem.2025.102066_bib41","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1080\/1547691X.2019.1605553","article-title":"Metal nanomaterials: Immune effects and implications of physicochemical properties on sensitization, elicitation, and exacerbation of allergic disease","volume":"16","author":"Roach","year":"2019","journal-title":"J Immunotoxicol"},{"issue":"11","key":"10.1016\/j.beem.2025.102066_bib42","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1038\/s41422-020-00395-4","article-title":"Manganese is critical for antitumor immune responses via cGAS-STING and improves the efficacy of clinical immunotherapy","volume":"30","author":"Lv","year":"2020","journal-title":"Cell Res"},{"key":"10.1016\/j.beem.2025.102066_bib43","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1146\/annurev-immunol-032414-112212","article-title":"Ion channels in innate and adaptive immunity","volume":"33","author":"Feske","year":"2015","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.beem.2025.102066_bib44","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/bs.ai.2019.11.007","article-title":"Metalloimmunology: the metal ion-controlled immunity","volume":"145","author":"Wang","year":"2020","journal-title":"Adv Immunol"},{"issue":"2","key":"10.1016\/j.beem.2025.102066_bib45","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1007\/s10787-023-01176-2","article-title":"COVID-19-induced neurological symptoms: focus on the role of metal ions","volume":"31","author":"Zhang","year":"2023","journal-title":"Inflammopharmacology"},{"issue":"1","key":"10.1016\/j.beem.2025.102066_bib46","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2024.2414546","article-title":"Pre-treatment of hyponatremia as a biomarker for poor immune prognosis in advanced or metastatic gastric cancer: a retrospective case analysis","volume":"20","author":"Pan","year":"2024","journal-title":"Hum Vaccin Immunother"},{"issue":"1","key":"10.1016\/j.beem.2025.102066_bib47","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2025.2535168","article-title":"Hyponatremia predicts immunotherapy resistance in biliary tract cancer","volume":"21","author":"Wang","year":"2025","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.beem.2025.102066_bib48","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.ejim.2016.07.028","article-title":"Hyponatremia, all-cause mortality, and risk of cancer diagnoses in the primary care setting: a large population study","volume":"36","author":"Selmer","year":"2016","journal-title":"Eur J Intern Med"},{"issue":"1","key":"10.1016\/j.beem.2025.102066_bib49","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1530\/EJE-15-0111","article-title":"Hyponatremia and mortality risk: a Danish cohort study of 279\u200a508 acutely hospitalized patients","volume":"173","author":"Holland-Bill","year":"2015","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"10.1016\/j.beem.2025.102066_bib50","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.lungcan.2009.05.015","article-title":"The occurrence of hyponatremia in SCLC and the influence on prognosis: a retrospective study of 453 patients treated in a single institution in a 10-year period","volume":"68","author":"Hansen","year":"2010","journal-title":"Lung Cancer"},{"issue":"14","key":"10.1016\/j.beem.2025.102066_bib51","doi-asserted-by":"crossref","first-page":"23871","DOI":"10.18632\/oncotarget.13372","article-title":"Hyponatremia normalization as an independent prognostic factor in patients with advanced non-small cell lung cancer treated with first-line therapy","volume":"8","author":"Berardi","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.beem.2025.102066_bib52","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1186\/s12885-015-1156-6","article-title":"Resolution of severe hyponatraemia is associated with improved survival in patients with cancer","volume":"15","author":"Balachandran","year":"2015","journal-title":"BMC Cancer"},{"issue":"3","key":"10.1016\/j.beem.2025.102066_bib53","doi-asserted-by":"crossref","DOI":"10.1093\/ckj\/sfaf023","article-title":"Correcting hyponatraemia is associated with improved survival in hyponatraemic metastatic cancer patients","volume":"18","author":"Ward","year":"2025","journal-title":"Clin Kidney J"},{"issue":"3","key":"10.1016\/j.beem.2025.102066_bib54","doi-asserted-by":"crossref","first-page":"G1","DOI":"10.1530\/EJE-13-1020","article-title":"Clinical practice guideline on diagnosis and treatment of hyponatraemia","volume":"170","author":"Spasovski","year":"2014","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.beem.2025.102066_bib55","article-title":"The use of an algorithm to aid diagnosis and treatment of patients with hyponatraemia secondary to SIADH","author":"Verbalis","year":"2010","journal-title":"12th Eur Congr Endocrinol"},{"issue":"6","key":"10.1016\/j.beem.2025.102066_bib56","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1111\/cen.13966","article-title":"Urea in cancer patients with chronic SIAD-induced hyponatremia: old drug, new evidence","volume":"90","author":"Nervo","year":"2019","journal-title":"Clin Endocrinol"},{"issue":"3","key":"10.1016\/j.beem.2025.102066_bib57","first-page":"125","article-title":"Urea for hyponatraemia due to the syndrome of inappropriate antidiuretic hormone secretion","volume":"78","author":"Woudstra","year":"2020","journal-title":"Neth J Med"},{"issue":"1","key":"10.1016\/j.beem.2025.102066_bib58","doi-asserted-by":"crossref","first-page":"10266","DOI":"10.1038\/s41598-022-14387-4","article-title":"Clinical efficacy of urea treatment in syndrome of inappropriate antidiuretic hormone secretion","volume":"12","author":"Perell\u00f3-Camacho","year":"2022","journal-title":"Sci Rep"},{"key":"10.1016\/j.beem.2025.102066_bib59","first-page":"1","article-title":"Advances on diagnosis of Helicobacter pylori infections","author":"Sousa","year":"2022","journal-title":"Crit Rev Microbiol"},{"issue":"4","key":"10.1016\/j.beem.2025.102066_bib60","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1210\/jc.2012-4082","article-title":"Clinical review: the use of vaptans in clinical endocrinology","volume":"98","author":"Peri","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"10.1016\/j.beem.2025.102066_bib61","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1016\/j.jacc.2006.08.039","article-title":"Emerging therapies for the management of decompensated heart failure: from bench to bedside","volume":"48","author":"deGoma","year":"2006","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"10.1016\/j.beem.2025.102066_bib62","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1634\/theoncologist.2011-0400","article-title":"Diagnosis and management of hyponatremia in cancer patients","volume":"17","author":"Castillo","year":"2012","journal-title":"Oncologist"},{"issue":"1","key":"10.1016\/j.beem.2025.102066_bib63","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1093\/jjco\/hyq170","article-title":"Clinical implication of the antidiuretic hormone (ADH) receptor antagonist mozavaptan hydrochloride in patients with ectopic ADH syndrome","volume":"41","author":"Yamaguchi","year":"2011","journal-title":"Jpn J Clin Oncol"},{"issue":"10","key":"10.1016\/j.beem.2025.102066_bib64","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1038\/nm935","article-title":"Inhibition of renal cystic disease development and progression by a vasopressin V2 receptor antagonist","volume":"9","author":"Gattone","year":"2003","journal-title":"Nat Med"},{"issue":"4","key":"10.1016\/j.beem.2025.102066_bib65","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1038\/nm1004","article-title":"Effective treatment of an orthologous model of autosomal dominant polycystic kidney disease","volume":"10","author":"Torres","year":"2004","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.beem.2025.102066_bib66","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1681\/ASN.2007060688","article-title":"Vasopressin directly regulates cyst growth in polycystic kidney disease","volume":"19","author":"Wang","year":"2008","journal-title":"J Am Soc Nephrol"},{"issue":"25","key":"10.1016\/j.beem.2025.102066_bib67","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1056\/NEJMoa1205511","article-title":"Tolvaptan in patients with autosomal dominant polycystic kidney disease","volume":"367","author":"Torres","year":"2012","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.beem.2025.102066_bib68","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/s12882-025-03960-4","article-title":"Commentary: tolvaptan for autosomal dominant polycystic kidney disease (ADPKD) - an update","volume":"26","author":"Gittus","year":"2025","journal-title":"BMC Nephrol"},{"issue":"2","key":"10.1016\/j.beem.2025.102066_bib69","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s11357-011-9347-9","article-title":"Chronic hyponatremia exacerbates multiple manifestations of senescence in male rats","volume":"35","author":"Barsony","year":"2013","journal-title":"Age"},{"issue":"3","key":"10.1016\/j.beem.2025.102066_bib70","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1007\/s12017-013-8235-0","article-title":"Low extracellular sodium causes neuronal distress independently of reduced osmolality in an experimental model of chronic hyponatremia","volume":"15","author":"Benvenuti","year":"2013","journal-title":"Neuromol Med"},{"issue":"2","key":"10.1016\/j.beem.2025.102066_bib71","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s40618-015-0352-1","article-title":"Neuronal distress induced by low extracellular sodium in vitro is partially reverted by the return to normal sodium","volume":"39","author":"Benvenuti","year":"2016","journal-title":"J Endocrinol Invest"},{"issue":"5","key":"10.1016\/j.beem.2025.102066_bib72","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1089\/ars.2004.6.878","article-title":"Heme oxygenase and its products in the nervous system","volume":"6","author":"Mancuso","year":"2004","journal-title":"Antioxid Redox Signal"},{"issue":"1","key":"10.1016\/j.beem.2025.102066_bib73","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1046\/j.1471-4159.2000.0750304.x","article-title":"Neurons overexpressing heme oxygenase-1 resist oxidative stress-mediated cell death","volume":"75","author":"Chen","year":"2000","journal-title":"J Neurochem"},{"issue":"3","key":"10.1016\/j.beem.2025.102066_bib74","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.biotechadv.2018.01.007","article-title":"Targeting of stress response pathways in the prevention and treatment of cancer","volume":"36","author":"Zelenka","year":"2018","journal-title":"Biotechnol Adv"},{"key":"10.1016\/j.beem.2025.102066_bib75","doi-asserted-by":"crossref","DOI":"10.1007\/s40618-022-01962-9","article-title":"Hyponatremia-related liver steatofibrosis and impaired spermatogenesis: evidence from a mouse model of the syndrome of inappropriate antidiuresis","author":"Marroncini","year":"2022","journal-title":"J Endocrinol Invest"},{"issue":"7","key":"10.1016\/j.beem.2025.102066_bib76","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1038\/s41575-019-0145-7","article-title":"From NASH to HCC: current concepts and future challenges","volume":"16","author":"Anstee","year":"2019","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"2","key":"10.1016\/j.beem.2025.102066_bib77","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/s12020-019-02135-0","article-title":"Effects of low extracellular sodium on proliferation and invasive activity of cancer cells in vitro","volume":"67","author":"Marroncini","year":"2020","journal-title":"Endocrine"},{"key":"10.1016\/j.beem.2025.102066_bib78","doi-asserted-by":"crossref","DOI":"10.1016\/j.mce.2021.111419","article-title":"Low sodium and tolvaptan have opposite effects in human small cell lung cancer cells","volume":"537","author":"Marroncini","year":"2021","journal-title":"Mol Cell Endocrinol"},{"issue":"1","key":"10.1016\/j.beem.2025.102066_bib79","doi-asserted-by":"crossref","first-page":"8067","DOI":"10.1038\/s41598-025-92674-6","article-title":"Effects of reduced extracellular sodium on proliferation and invasive activity of renal cell carcinoma cell lines","volume":"15","author":"Naldi","year":"2025","journal-title":"Sci Rep"},{"issue":"4","key":"10.1016\/j.beem.2025.102066_bib80","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15041197","article-title":"Hyponatremia and cancer: from bedside to benchside","volume":"15","author":"Fibbi","year":"2023","journal-title":"Cancers"},{"issue":"32","key":"10.1016\/j.beem.2025.102066_bib81","doi-asserted-by":"crossref","first-page":"E6603","DOI":"10.1073\/pnas.1706011114","article-title":"Rho-associated kinase is a therapeutic target in neuroblastoma","volume":"114","author":"Dyberg","year":"2017","journal-title":"Proc Natl Acad Sci USA"},{"issue":"5","key":"10.1016\/j.beem.2025.102066_bib82","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1097\/CAD.0000000000000490","article-title":"RhoA\/ROCK pathway inhibition by fasudil suppresses the vasculogenic mimicry of U2OS osteosarcoma cells in vitro","volume":"28","author":"Xia","year":"2017","journal-title":"Anticancer Drugs"},{"issue":"7","key":"10.1016\/j.beem.2025.102066_bib83","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1158\/1535-7163.MCT-14-0523","article-title":"Rho kinase inhibitor fasudil suppresses the vasculogenic mimicry of B16 mouse melanoma cells both in vitro and in vivo","volume":"14","author":"Xia","year":"2015","journal-title":"Mol Cancer Ther"},{"issue":"23","key":"10.1016\/j.beem.2025.102066_bib84","doi-asserted-by":"crossref","DOI":"10.3390\/ijms242316680","article-title":"Hyponatremia promotes cancer growth in a murine xenograft model of neuroblastoma","volume":"24","author":"Marroncini","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"8","key":"10.1016\/j.beem.2025.102066_bib85","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1681\/ASN.2006030251","article-title":"Increased water intake decreases progression of polycystic kidney disease in the PCK rat","volume":"17","author":"Nagao","year":"2006","journal-title":"J Am Soc Nephrol"},{"issue":"5","key":"10.1016\/j.beem.2025.102066_bib86","doi-asserted-by":"crossref","first-page":"F1005","DOI":"10.1152\/ajprenal.00243.2011","article-title":"Tolvaptan inhibits ERK-dependent cell proliferation, Cl\u2212 secretion, and in vitro cyst growth of human ADPKD cells stimulated by vasopressin","volume":"301","author":"Reif","year":"2011","journal-title":"Am J Physiol Ren Physiol"},{"issue":"3","key":"10.1016\/j.beem.2025.102066_bib87","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1007\/s11030-022-10482-w","article-title":"MD simulation-based screening approach identified tolvaptan as a potential inhibitor of Eg5","volume":"27","author":"Sebastian","year":"2023","journal-title":"Mol Divers"},{"issue":"4","key":"10.1016\/j.beem.2025.102066_bib88","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.bcp.2015.03.015","article-title":"Mechanisms of tolvaptan-induced toxicity in HepG2 cells","volume":"95","author":"Wu","year":"2015","journal-title":"Biochem Pharm"},{"issue":"9","key":"10.1016\/j.beem.2025.102066_bib89","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1007\/s40618-022-01807-5","article-title":"The V(2) receptor antagonist tolvaptan counteracts proliferation and invasivity in human cancer cells","volume":"45","author":"Marroncini","year":"2022","journal-title":"J Endocrinol Invest"},{"issue":"15","key":"10.1016\/j.beem.2025.102066_bib90","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25158402","article-title":"The vasopressin receptor antagonist tolvaptan counteracts tumor growth in a murine xenograft model of small cell lung cancer","volume":"25","author":"Naldi","year":"2024","journal-title":"Int J Mol Sci"},{"issue":"6","key":"10.1016\/j.beem.2025.102066_bib91","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1038\/s41388-019-1059-0","article-title":"Targeting the vasopressin type-2 receptor for renal cell carcinoma therapy","volume":"39","author":"Sinha","year":"2020","journal-title":"Oncogene"},{"issue":"5","key":"10.1016\/j.beem.2025.102066_bib92","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12051185","article-title":"Therapeutic targeting of autophagy for renal cell carcinoma therapy","volume":"12","author":"Jones","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.beem.2025.102066_bib93","doi-asserted-by":"crossref","first-page":"17009","DOI":"10.1038\/nrdp.2017.9","article-title":"Renal cell carcinoma","volume":"3","author":"Hsieh","year":"2017","journal-title":"Nat Rev Dis Prim"},{"issue":"1","key":"10.1016\/j.beem.2025.102066_bib94","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1006\/bbrc.1994.1236","article-title":"Binding of [3H] SR 49059, a potent nonpeptide vasopressin V1a antagonist, to rat and human liver membranes","volume":"199","author":"Serradeil-Le Gal","year":"1994","journal-title":"Biochem Biophys Res Commun"},{"issue":"12","key":"10.1016\/j.beem.2025.102066_bib95","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1038\/sj.ki.5000432","article-title":"Vasopressin receptor antagonists","volume":"69","author":"Greenberg","year":"2006","journal-title":"Kidney Int"},{"issue":"15","key":"10.1016\/j.beem.2025.102066_bib96","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1007\/s00018-006-6054-2","article-title":"Vasopressin antagonists","volume":"63","author":"Lemmens-Gruber","year":"2006","journal-title":"Cell Mol Life Sci"},{"issue":"5","key":"10.1016\/j.beem.2025.102066_bib97","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1111\/j.1471-0528.2000.tb13302.x","article-title":"Effect of SR49059, an orally active V1a vasopressin receptor antagonist, in the prevention of dysmenorrhoea","volume":"107","author":"Brouard","year":"2000","journal-title":"BJOG"},{"issue":"9624","key":"10.1016\/j.beem.2025.102066_bib98","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1016\/S0140-6736(08)60695-9","article-title":"Non-peptide arginine-vasopressin antagonists: the vaptans","volume":"371","author":"Decaux","year":"2008","journal-title":"Lancet"},{"issue":"498","key":"10.1016\/j.beem.2025.102066_bib99","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaw4636","article-title":"Arginine vasopressin receptor 1a is a therapeutic target for castration-resistant prostate cancer","volume":"11","author":"Zhao","year":"2019","journal-title":"Sci Transl Med"},{"issue":"8","key":"10.1016\/j.beem.2025.102066_bib100","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1158\/1541-7786.MCR-21-0927","article-title":"Exploiting dependence of castration-resistant prostate cancer on the arginine vasopressin signaling axis by repurposing vaptans","volume":"20","author":"Heidman","year":"2022","journal-title":"Mol Cancer Res"}],"container-title":["Best Practice & Research Clinical Endocrinology & Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521690X25000995?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521690X25000995?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T15:23:31Z","timestamp":1787153011000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521690X25000995"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":100,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S1521690X25000995"],"URL":"https:\/\/doi.org\/10.1016\/j.beem.2025.102066","relation":{},"ISSN":["1521-690X"],"issn-type":[{"value":"1521-690X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hyponatraemia and cancer","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Endocrinology & Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.beem.2025.102066","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102066"}}